Amount of consideration receivable in pursuant to the sale of future revenue interest.

No definition available.

Name:	obio_ConsiderationReceivableFromSaleOfFutureRevenuesInterests
Namespace Prefix:	obio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of tranches in which investment amount shall be paid.

+ References

No definition available.

+ Details

Name:	obio_NumberOfTranches
Namespace Prefix:	obio_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of cash inflow from Revenue interest purchase agreement entered .

+ References

No definition available.

+ Details

Name:	obio_ProceedsFromRevenueInterestPurchaseAgreement
Namespace Prefix:	obio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	obio_RevenueInterestPurchaseAgreementsDetailsLineItems
Namespace Prefix:	obio_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of revenues remitted related to products until threshold limit.

+ References

No definition available.

+ Details

Name:	obio_RevenuePaymentInitialPrepaymentRate
Namespace Prefix:	obio_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of revenues remitted related to products after threshold limit.

+ References

No definition available.

+ Details

Name:	obio_RevenuePaymentPrepaymentRatePostThresholdAmount
Namespace Prefix:	obio_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of threshold for revenue repayments during the period.

+ References

No definition available.

+ Details

Name:	obio_RevenueRepaymentThresholdAmountMonetaryDurationDebit
Namespace Prefix:	obio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Percentage of revenue sharing being a Applicable Purchaser Revenue Interest Rate.

+ References

No definition available.

+ Details

Name:	obio_RevenueSharingPercentageApplicablePurchaserRevenueInterestRate
Namespace Prefix:	obio_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of royalty that is paid on the funded amount as per the agreement.

+ References

No definition available.

+ Details

Name:	obio_RoyaltyRateOnFundedAmount
Namespace Prefix:	obio_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

+ Details

Name:	us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

+ Details

Name:	us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482949/835-30-55-8

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482900/835-30-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-6

+ Details

Name:	us-gaap_DebtInstrumentInterestRateEffectivePercentage
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

+ Details

Name:	us-gaap_WarrantsAndRightsOutstandingTerm
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=obio_LigandWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=obio_RevenueParticipationRightPurchaseAndSaleAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=obio_AvimTherapyAndVirtueSabProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=obio_AvimTherapyProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=obio_LigandPharmaceuticalsIncorporatedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=obio_RoyaltyRateApplicableUntilSecondInstallmentIsPaidMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=obio_AnnualNetSalesLessThanOrEqualTo100MillionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=obio_AnnualNetSalesGreaterThanOrEqualTo100MillionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_VestingAxis=obio_TrancheOnePaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_VestingAxis=obio_TrancheTwoPaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=obio_VirtueSabProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=obio_LigandStockPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Royalty Purchase Agreement - Other (Details) $ / shares in Units, $ in Millions	May 01, 2026 USD ($) shares	Aug. 04, 2025 USD ($) tranche $ / shares shares	Jul. 31, 2025 USD ($) shares	Mar. 31, 2026 $ / shares	Dec. 31, 2025
Ligand Warrant
Royalty Purchase Agreement
Price per share (in dollars per share) \| $ / shares				$ 3.67
Term				9 years 4 months 2 days
Revenue Participation Right Purchase and Sale Agreement \| AVIM Therapy and Virtue Sab Products ("Products") \| Ligand Warrant
Royalty Purchase Agreement
Percentage of revenue repayment			17.00%
Amount of revenue repayment			$ 17.0
Revenue Participation Right Purchase and Sale Agreement \| Avim Therapy Products \| Ligand Warrant
Royalty Purchase Agreement
Threshold amount of revenue repayment			4.00%
Ligand Pharmaceuticals Incorporated (the "Purchaser") \| Revenue Participation Right Purchase and Sale Agreement
Royalty Purchase Agreement
Investment amount			$ 35.0
Interest rate				23.30%	23.10%
Ligand Pharmaceuticals Incorporated (the "Purchaser") \| Revenue Participation Right Purchase and Sale Agreement \| AVIM Therapy and Virtue Sab Products ("Products")
Royalty Purchase Agreement
Number of tranches \| tranche		2
Ligand Pharmaceuticals Incorporated (the "Purchaser") \| Revenue Participation Right Purchase and Sale Agreement \| AVIM Therapy and Virtue Sab Products ("Products") \| Royalty Rate Applicable Until Second Installment Is Paid
Royalty Purchase Agreement
Percentage of royalty funded amount as per the agreement			57.10%
Ligand Pharmaceuticals Incorporated (the "Purchaser") \| Revenue Participation Right Purchase and Sale Agreement \| AVIM Therapy and Virtue Sab Products ("Products") \| Minimum \| Annual Net Sales of the products are less than or equal to $100 million
Royalty Purchase Agreement
Revenue sharing percentage (%)			17.00%
Ligand Pharmaceuticals Incorporated (the "Purchaser") \| Revenue Participation Right Purchase and Sale Agreement \| AVIM Therapy and Virtue Sab Products ("Products") \| Minimum \| Annual Net Sales of the products are greater than or equal to $100 million
Royalty Purchase Agreement
Revenue sharing percentage (%)			4.00%
Ligand Pharmaceuticals Incorporated (the "Purchaser") \| Revenue Participation Right Purchase and Sale Agreement \| AVIM Therapy and Virtue Sab Products ("Products") \| Maximum \| Annual Net Sales of the products are less than or equal to $100 million
Royalty Purchase Agreement
Revenue sharing percentage (%)			20.00%
Ligand Pharmaceuticals Incorporated (the "Purchaser") \| Revenue Participation Right Purchase and Sale Agreement \| AVIM Therapy and Virtue Sab Products ("Products") \| Maximum \| Annual Net Sales of the products are greater than or equal to $100 million
Royalty Purchase Agreement
Revenue sharing percentage (%)			7.00%
Ligand Pharmaceuticals Incorporated (the "Purchaser") \| Revenue Participation Right Purchase and Sale Agreement \| AVIM Therapy and Virtue Sab Products ("Products") \| Tranche One
Royalty Purchase Agreement
Proceeds from the royalty purchase agreement		$ 20.0
Ligand Pharmaceuticals Incorporated (the "Purchaser") \| Revenue Participation Right Purchase and Sale Agreement \| AVIM Therapy and Virtue Sab Products ("Products") \| Tranche Two
Royalty Purchase Agreement
Investment amount	$ 15.0
Ligand Pharmaceuticals Incorporated (the "Purchaser") \| Revenue Participation Right Purchase and Sale Agreement \| Virtue Sab Products
Royalty Purchase Agreement
Threshold amount of revenue repayment			4.00%
Ligand Pharmaceuticals Incorporated (the "Purchaser") \| Ligand Stock Purchase Agreement \| Ligand Warrant
Royalty Purchase Agreement
Price per share (in dollars per share) \| $ / shares		$ 3.67
Term			10 years
Ligand Pharmaceuticals Incorporated (the "Purchaser") \| Ligand Stock Purchase Agreement \| Ligand Warrant \| Maximum
Royalty Purchase Agreement
Number of warrants to be issued \| shares		2,000,000
Ligand Pharmaceuticals Incorporated (the "Purchaser") \| Ligand Stock Purchase Agreement \| Tranche One \| Ligand Warrant
Royalty Purchase Agreement
Number of warrants to be issued \| shares			1,142,857
Ligand Pharmaceuticals Incorporated (the "Purchaser") \| Ligand Stock Purchase Agreement \| Tranche Two \| Ligand Warrant
Royalty Purchase Agreement
Number of warrants to be issued \| shares	857,143